(GSK) GlaxoSmithKline - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US37733W2044
Stock: Vaccines, Oncology, Respiratory, HIV, Antibiotics
Total Rating 67
Risk 66
Buy Signal 0.49
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.20% |
| Yield on Cost 5y | 5.89% |
| Yield CAGR 5y | -11.31% |
| Payout Consistency | 90.9% |
| Payout Ratio | 38.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.7% |
| Relative Tail Risk | -6.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.96 |
| Alpha | 59.98 |
| Character TTM | |
|---|---|
| Beta | 0.221 |
| Beta Downside | 0.178 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.46% |
| CAGR/Max DD | 0.84 |
Description: GSK GlaxoSmithKline January 29, 2026
GSK plc (NYSE:GSK) is a global healthcare company that develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the United Kingdom, United States, and other markets. Its operations are split between Commercial Operations and Total R&D, covering therapeutic areas such as oncology, respiratory-immunology, inflammation, and infectious diseases.
Key recent metrics (FY 2023): revenue $46.8 bn, net income $5.2 bn, and R&D spend $7.1 bn (≈15 % of sales). The dividend yield stands at roughly 5.1 % and the company returned $5.5 bn to shareholders via buybacks and dividends. The vaccine portfolio generated $4.3 bn in sales, driven by strong demand for Shingles (Shingrix) and RSV immunizations.
Sector drivers shaping GSK’s outlook include an aging global population that lifts demand for chronic-disease treatments, sustained government and private-sector investment in mRNA vaccine platforms (evidenced by the CureVac partnership), and regulatory pressures that favor large, diversified pharma firms capable of navigating complex approval pathways.
For a deeper, data-rich valuation framework, you may find it useful to explore GSK’s analyst-level metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 5.71b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.40 > 1.0 |
| NWC/Revenue: -11.90% < 20% (prev -14.98%; Δ 3.08% < -1%) |
| CFO/TA 0.14 > 3% & CFO 8.30b > Net Income 5.71b |
| Net Debt (14.30b) to EBITDA (11.42b): 1.25 < 3 |
| Current Ratio: 0.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago -1.42% < -2% |
| Gross Margin: 72.46% > 18% (prev 0.71%; Δ 7175 % > 0.5%) |
| Asset Turnover: 54.04% > 50% (prev 52.77%; Δ 1.28% > 0%) |
| Interest Coverage Ratio: 11.33 > 6 (EBITDA TTM 11.42b / Interest Expense TTM 698.6m) |
Altman Z'' 1.28
| A: -0.06 (Total Current Assets 17.48b - Total Current Liabilities 21.35b) / Total Assets 61.01b |
| B: 0.17 (Retained Earnings 10.19b / Total Assets 61.01b) |
| C: 0.13 (EBIT TTM 7.92b / Avg Total Assets 60.24b) |
| D: 0.26 (Book Value of Equity 11.54b / Total Liabilities 45.02b) |
| Altman-Z'' Score: 1.28 = BB |
Beneish M -2.85
| DSRI: 1.24 (Receivables 7.75b/6.00b, Revenue 32.55b/31.38b) |
| GMI: 0.98 (GM 72.46% / 71.16%) |
| AQI: 1.01 (AQ_t 0.55 / AQ_t-1 0.54) |
| SGI: 1.04 (Revenue 32.55b / 31.38b) |
| TATA: -0.04 (NI 5.71b - CFO 8.30b) / TA 61.01b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of GSK shares?
As of February 07, 2026, the stock is trading at USD 60.23 with a total of 8,147,954 shares traded.
Over the past week, the price has changed by +16.72%, over one month by +19.13%, over three months by +28.99% and over the past year by +72.67%.
Over the past week, the price has changed by +16.72%, over one month by +19.13%, over three months by +28.99% and over the past year by +72.67%.
Is GSK a buy, sell or hold?
GlaxoSmithKline has received a consensus analysts rating of 2.88.
Therefor, it is recommend to hold GSK.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the GSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.2 | -11.6% |
| Analysts Target Price | 53.2 | -11.6% |
| ValueRay Target Price | 75.8 | 25.8% |
GSK Fundamental Data Overview February 07, 2026
P/E Trailing = 15.5711
P/E Forward = 10.846
P/S = 3.6346
P/B = 5.1474
P/EG = 0.4823
Revenue TTM = 32.55b USD
EBIT TTM = 7.92b USD
EBITDA TTM = 11.42b USD
Long Term Debt = 14.71b USD (from longTermDebt, last quarter)
Short Term Debt = 3.01b USD (from shortTermDebt, last quarter)
Debt = 17.69b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.30b USD (from netDebt column, last quarter)
Enterprise Value = 133.02b USD (118.73b + Debt 17.69b - CCE 3.40b)
Interest Coverage Ratio = 11.33 (Ebit TTM 7.92b / Interest Expense TTM 698.6m)
EV/FCF = 21.33x (Enterprise Value 133.02b / FCF TTM 6.24b)
FCF Yield = 4.69% (FCF TTM 6.24b / Enterprise Value 133.02b)
FCF Margin = 19.15% (FCF TTM 6.24b / Revenue TTM 32.55b)
Net Margin = 17.53% (Net Income TTM 5.71b / Revenue TTM 32.55b)
Gross Margin = 72.46% ((Revenue TTM 32.55b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 69.38% (prev 73.58%)
Tobins Q-Ratio = 2.18 (Enterprise Value 133.02b / Total Assets 61.01b)
Interest Expense / Debt = 1.05% (Interest Expense 185.6m / Debt 17.69b)
Taxrate = 23.47% (220.1m / 937.6m)
NOPAT = 6.06b (EBIT 7.92b * (1 - 23.47%))
Current Ratio = 0.82 (Total Current Assets 17.48b / Total Current Liabilities 21.35b)
Debt / Equity = 1.08 (Debt 17.69b / totalStockholderEquity, last quarter 16.35b)
Debt / EBITDA = 1.25 (Net Debt 14.30b / EBITDA 11.42b)
Debt / FCF = 2.29 (Net Debt 14.30b / FCF TTM 6.24b)
Total Stockholder Equity = 19.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.48% (Net Income 5.71b / Total Assets 61.01b)
RoE = 29.79% (Net Income TTM 5.71b / Total Stockholder Equity 19.16b)
RoCE = 23.38% (EBIT 7.92b / Capital Employed (Equity 19.16b + L.T.Debt 14.71b))
RoIC = 40.30% (NOPAT 6.06b / Invested Capital 15.03b)
WACC = 5.96% (E(118.73b)/V(136.42b) * Re(6.73%) + D(17.69b)/V(136.42b) * Rd(1.05%) * (1-Tc(0.23)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.39%
[DCF Debug] Terminal Value 84.80% ; FCFF base≈5.36b ; Y1≈4.77b ; Y5≈4.00b
Fair Price DCF = 51.95 (EV 118.55b - Net Debt 14.30b = Equity 104.25b / Shares 2.01b; r=5.96% [WACC]; 5y FCF grow -13.61% → 2.90% )
EPS Correlation: 14.32 | EPS CAGR: -11.19% | SUE: 0.70 | # QB: 0
Revenue Correlation: 73.55 | Revenue CAGR: 4.58% | SUE: -0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.18 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=4.81 | Chg30d=+0.159 | Revisions Net=+1 | Growth EPS=+2.2% | Growth Revenue=+3.9%
EPS next Year (2027-12-31): EPS=5.15 | Chg30d=+0.348 | Revisions Net=+2 | Growth EPS=+7.0% | Growth Revenue=+4.8%
P/E Forward = 10.846
P/S = 3.6346
P/B = 5.1474
P/EG = 0.4823
Revenue TTM = 32.55b USD
EBIT TTM = 7.92b USD
EBITDA TTM = 11.42b USD
Long Term Debt = 14.71b USD (from longTermDebt, last quarter)
Short Term Debt = 3.01b USD (from shortTermDebt, last quarter)
Debt = 17.69b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.30b USD (from netDebt column, last quarter)
Enterprise Value = 133.02b USD (118.73b + Debt 17.69b - CCE 3.40b)
Interest Coverage Ratio = 11.33 (Ebit TTM 7.92b / Interest Expense TTM 698.6m)
EV/FCF = 21.33x (Enterprise Value 133.02b / FCF TTM 6.24b)
FCF Yield = 4.69% (FCF TTM 6.24b / Enterprise Value 133.02b)
FCF Margin = 19.15% (FCF TTM 6.24b / Revenue TTM 32.55b)
Net Margin = 17.53% (Net Income TTM 5.71b / Revenue TTM 32.55b)
Gross Margin = 72.46% ((Revenue TTM 32.55b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 69.38% (prev 73.58%)
Tobins Q-Ratio = 2.18 (Enterprise Value 133.02b / Total Assets 61.01b)
Interest Expense / Debt = 1.05% (Interest Expense 185.6m / Debt 17.69b)
Taxrate = 23.47% (220.1m / 937.6m)
NOPAT = 6.06b (EBIT 7.92b * (1 - 23.47%))
Current Ratio = 0.82 (Total Current Assets 17.48b / Total Current Liabilities 21.35b)
Debt / Equity = 1.08 (Debt 17.69b / totalStockholderEquity, last quarter 16.35b)
Debt / EBITDA = 1.25 (Net Debt 14.30b / EBITDA 11.42b)
Debt / FCF = 2.29 (Net Debt 14.30b / FCF TTM 6.24b)
Total Stockholder Equity = 19.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.48% (Net Income 5.71b / Total Assets 61.01b)
RoE = 29.79% (Net Income TTM 5.71b / Total Stockholder Equity 19.16b)
RoCE = 23.38% (EBIT 7.92b / Capital Employed (Equity 19.16b + L.T.Debt 14.71b))
RoIC = 40.30% (NOPAT 6.06b / Invested Capital 15.03b)
WACC = 5.96% (E(118.73b)/V(136.42b) * Re(6.73%) + D(17.69b)/V(136.42b) * Rd(1.05%) * (1-Tc(0.23)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.39%
[DCF Debug] Terminal Value 84.80% ; FCFF base≈5.36b ; Y1≈4.77b ; Y5≈4.00b
Fair Price DCF = 51.95 (EV 118.55b - Net Debt 14.30b = Equity 104.25b / Shares 2.01b; r=5.96% [WACC]; 5y FCF grow -13.61% → 2.90% )
EPS Correlation: 14.32 | EPS CAGR: -11.19% | SUE: 0.70 | # QB: 0
Revenue Correlation: 73.55 | Revenue CAGR: 4.58% | SUE: -0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.18 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=4.81 | Chg30d=+0.159 | Revisions Net=+1 | Growth EPS=+2.2% | Growth Revenue=+3.9%
EPS next Year (2027-12-31): EPS=5.15 | Chg30d=+0.348 | Revisions Net=+2 | Growth EPS=+7.0% | Growth Revenue=+4.8%